Synthesis, Preclinical Toxicity, and Biodistribution of [18F]AVT-011 to Assess the P-Glycoprotein Function

被引:0
|
作者
Thakur, Riptee [1 ]
Kumar, Manoj [1 ]
Kumar, Aishwarya [1 ]
Joshi, Raman Kumar [1 ]
Maheshwari, Divya [2 ]
Km, Afsal Mohammed [3 ]
Venkataswamy, Manjunatha [4 ]
Mohanty, Bhabani [5 ]
Chaudhari, Pradip [5 ]
Mohan, Hosahalli K. [6 ]
Kumar, Pardeep [1 ]
机构
[1] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuroimaging & Intervent Radiol, Bengaluru, India
[2] Avaant Imaging, Lexington, MA USA
[3] Esente Healthcare, Bengaluru, India
[4] NIMHANS, Dept Neurovirol, Bengaluru, India
[5] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc ACTREC, Anim Oncol Grp, Mumbai, India
[6] Sri Shankara Canc Hosp & Res Ctr, Dept Nucl Med, Bengaluru, India
关键词
chemoresistance; P-glycoprotein; radiochemistry; micro-PET; DRUG-RESISTANCE; BRAIN;
D O I
10.1089/cbr.2024.0114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Many studies have reported the role of P-glycoprotein (Pgp) in chemoresistance in various pathological conditions such as cancer and neurodegenerative diseases, such as Alzheimer's. In this study, we are reporting the high-performance liquid chromatography (HPLC)-based purification of fluorine-18 [F-18]AVT-011 and its preclinical evaluation. Methods: AVT-011 was labeled with F-18 using the nucleophilic substitution method by heating the reaction mixture at 110 degrees C for 10 min, followed by purification using preparative HPLC and C18ec cartridge. The in vitro cell uptake study was carried out in U87 cells with and without an inhibitor. The preclinical toxicity was carried out in CD1 mice in three groups, including control, AVT-011 treated, and [F-18]AVT-011 treated. The biodistribution study was done in CD1 mice (n = 12) after intravenous injection of 4-6 MBq [F-18]AVT-011, and mice were sacrificed at various time intervals. A dose of 3.7 +/- 0.7 MBq of [F-18]AVT-011 was injected intravenously in the healthy Swiss albino mice, and the whole-body micro-positron emission tomography was acquired at 0-, 30-, 60-, and 120-min postinjection. Results: The radiochemical purity of [F-18]AVT-011 was 97 +/- 1.5% as evaluated by radio-HPLC with a yield of 14 +/- 2% and was stable up to 95% under in vitro conditions in blood and in vivo conditions up to 4 h. The in vitro cell uptake study showed a significant difference in control (27.4 +/- 2.1%) and blocked U987 cells (73.2 +/- 3.2%) after incubation of 120 min. The tissue distribution in mice showed the highest uptake in the liver (17.3 +/- 2.4%), kidneys (16.6 +/- 3.1%), lungs (10.4 +/- 2.9%), and spleen (5.6 +/- 0.8%) at 15 min, and the activity was washed out with time. The radioactivity cleared through the hepatorenal pathway. The animal imaging study also demonstrates a similar biodistribution pattern. Conclusions: [F-18]AVT-011 showed higher specific activity than the cartridge-based method but showed similar biological activity.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [1] In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance
    Pavitra Kannan
    András Füredi
    Sabina Dizdarevic
    Thomas Wanek
    Severin Mairinger
    Jeffrey Collins
    Theresa Falls
    R. Michael van Dam
    Divya Maheshwari
    Jason T. Lee
    Gergely Szakács
    Oliver Langer
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2026 - 2035
  • [2] In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance
    Kannan, Pavitra
    Fueredi, Andras
    Dizdarevic, Sabina
    Wanek, Thomas
    Mairinger, Severin
    Collins, Jeffrey
    Falls, Theresa
    van Dam, R. Michael
    Maheshwari, Divya
    Lee, Jason T.
    Szakacs, Gergely
    Langer, Oliver
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (08) : 2026 - 2035
  • [3] Biodistribution and microPET imaging studies of the chemotherapy analogue and p-glycoprotein substrate [18F]-fluoropaclitaxel
    Gangloff, A
    Kesner, AL
    Hsueh, WA
    Kiesewetter, DO
    Eckelman, W
    Czernin, J
    Pegram, M
    Beryt, M
    Silverman, DH
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 374P - 374P
  • [4] Is [18F]-pMPPF a P-glycoprotein substrate in human?
    Tournier, N.
    Valette, H.
    Goutal, S.
    Schollhorn, M.
    Saba, W.
    Cisternino, S.
    Scherrmann, J.
    Bottlaender, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S210 - S210
  • [5] Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier
    Toyohara, Jun
    Sakata, Muneyuki
    Tago, Tetsuro
    Colabufo, Nicola A.
    Luurtsema, Gert
    EJNMMI RESEARCH, 2020, 10 (01)
  • [6] Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier
    Jun Toyohara
    Muneyuki Sakata
    Tetsuro Tago
    Nicola A. Colabufo
    Gert Luurtsema
    EJNMMI Research, 10
  • [7] 2′[18F]-fluoroethylrhodamine B is a promising radiotracer to measure P-glycoprotein function
    Trencsenyi, Gyoergy
    Kertesz, Istvan
    Krasznai, Zoard T.
    Mate, Gabor
    Szaloki, Gabor
    Judit, P. Szabo
    Karpati, Levente
    Krasznai, Zoltan
    Marian, Terez
    Goda, Katalin
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 74 : 27 - 35
  • [8] Synthesis of an 18F labelled analogue of the P-glycoprotein substrate PET tracer verapamil
    Raaphorst, Renske M.
    Savolainen, Heli
    Lammertsma, Adriaan A.
    Elsinga, Philip H.
    Luurtsema, Gert
    Windhorst, Albert D.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 : S343 - S343
  • [9] To study uptake of 18F-AVT-011 in different cell lines expressing p-glycoprotein.
    Thakur, R.
    Kumar, M.
    Chaudhari, P.
    Kumar, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S436 - S436
  • [10] Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats
    Passchier, J
    van Waarde, A
    Doze, P
    Elsinga, PH
    Vaalburg, W
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 407 (03) : 273 - 280